Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | ARG1 | P05089 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MASP2 | O00187 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31524208 | 1.00 | HRH3 (0.55) | HRH3GRIK1F2ARG1MEN1 | |
| SCHEMBL31080928 | 1.00 | HRH3 (0.55) | HRH3GRIK1F2ARG1MEN1 | |
| SCHEMBL31080931 | 1.00 | HRH3 (0.55) | HRH3GRIK1F2ARG1MEN1 | |
| SCHEMBL11234759 | 1.00 | HRH3 (0.55) | HRH3GRIK1F2ARG1MEN1 | |
| SCHEMBL30471654 | 0.87 | HRH3 (0.54) | HRH3GRIK1F2MEN1KMT2A | |
| SCHEMBL19292680 | 0.86 | HRH3 (0.54) | HRH3GRIK1F2ARG1MASP2 | |
| SCHEMBL22536533 | 0.86 | HRH3 (0.54) | HRH3GRIK1F2ARG1MASP2 | |
| SCHEMBL1706921 | 0.86 | HRH3 (0.54) | HRH3GRIK1F2ARG1MASP2 | |
| SCHEMBL199035 | 0.86 | HRH3 (0.54) | HRH3GRIK1F2ARG1MASP2 | |
| SCHEMBL199034 | 0.86 | HRH3 (0.54) | HRH3GRIK1F2ARG1MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558246-B1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-7659305-B2 | 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. | PFIZER INC. (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1558246-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20040132801-A1 | Therapeutic proline derivatives | RAWSON DAVID JAMES (GB) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039367-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LIMITED (GN) | 2004-05-13 | — | — | WO | disclosed |
| US-4316905-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132801-A1 | Therapeutic proline derivatives | PRRC2C, SLC6A7, FAAH | HRH3 516/4885GRIK1 449/4885F2 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.